Korean Pharma Obtains Approval for Oral Cognitive Enhancer... Insurance Reimbursement Listing Expected Next Month

Korea Pharma announced on the 16th that it has obtained product approval from the Ministry of Food and Drug Safety for the oral cognitive enhancer ‘Pharmanisergoline Tablets 30mg’.

This enhancer is used as a primary treatment for memory impairment, concentration disorders, and judgment disorders related to primary degenerative vascular dementia and mixed dementia. It acts as an alpha-1 (α1) adrenergic receptor antagonist, dilating blood vessels to increase arterial blood flow and inhibiting platelet aggregation, thereby promoting metabolic activity.

A company representative stated, “Its indications are similar to those of the domestic leading cognitive enhancer ‘Choline Alfoscerate,’ which records annual sales of 600 billion KRW, so we expect a high possibility of substitution,” and added, “We are currently proceeding with procedures aiming for insurance reimbursement registration next month.”

Korea Pharma has obtained product approvals this year for various products including the cognitive enhancer, the antidepressant ‘Pharmades Venlafaxine Extended-Release Tablets,’ and the onychomycosis treatment ‘Pharma Efinaconazole Topical Solution.’ The strategy is to expand sales by increasing the number of new product lines and improve profitability by reducing the sales proportion of low-profit products.

Korea Pharma emphasized, “We recorded somewhat sluggish first-half performance due to the medical sector strike and contract suspensions with overseas partners,” and stressed, “We will lay the foundation for performance growth through various achievements in generic new products and improved new drugs, as well as strategic alliances with global pharmaceutical companies.”